ViroStatics is a privately held small pharmaceutical company dedicated to the discovery and the development of novel compounds for a multifaceted treatment of cancers and viral diseases, focusing on novel, selective, host cell kinase targeted inhibitors.
The Team and Advisors combines scientific, business, legal, and technology expertise, spanning the entire process of drug development from translational science through preclinical and clinical drug development.
ViroStatics intends to license its compounds at the preclinical stage, with a patent protection extended until 2039.
Developing Novel Compounds Targeting Cancers and Viruses
The Company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinase selectivity, efficacy and safety profiles.
Consistent with its well defined mechanism of action, ViroStatics’ lead compound has a good toxicity profile while exerting potent activity in preclinical models against most aggressive cancers with high unmet need such as pancreatic cancer, highly malignant lymphoma and acute leukemia, lung cancer and breast cancer.
LEARN MOREViroStatics awarded with H2020 Seal of Excellence
28 November 2017
The project proposal ICARUS related to Completing preclinical studies (IMPD-Enabling package) to bring the novel CDK4/6/9 inhibitor VS2-370 to the clinic for aggressive tumors and with the potential for HIV Cure under the Horizon 2020’s SME instrument Phase 2 call H2020-SME Inst-03-2016-2017 in the area of Dedicated support to biotechnology SMEs closing the gap from lab to market by ViroStatics following evaluation by an international panel of independent experts WAS SCORED AS A HIGH-QUALITY PROJECT PROPOSAL IN A HIGHLY COMPETITIVE EVALUATION PROCESS